Diabetes & vascular disease research最新文献

{"title":"Estimated glucose disposal rate and microvascular complications of diabetes mellitus type I: A systematic review and meta-analysis.","authors":"Diar Zooravar, Hanieh Radkhah, Bahareh Shateri Amiri, Pedram Soltani","doi":"10.1177/14791641251324612","DOIUrl":"10.1177/14791641251324612","url":null,"abstract":"<p><p><b>Objectives:</b> This study aims to assess the association between the estimated glucose disposal rate (eGDR) and the risk of diabetic microvascular complications in patients with T1DM.<b>Methods:</b> A systematic search of PubMed, Scopus, and Web of Science was conducted up to August 2024, including studies that examined the relationship between eGDR and diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic neuropathy (DN) in patients with T1DM. A meta-analysis was performed to compare the eGDR values in patients with and without microvascular complications and assess the risk of these complications.<b>Results:</b> 22 studies were included. Lower eGDR values were significantly associated with a higher risk of microvascular complications. Specifically, a one-unit increase in eGDR was associated with a 18% reduction in the risk of DKD (ES: 0.82, 95% CI: 0.74-0.92), a 21% reduction in the risk of DR (OR: 0.79, 95% CI: 0.73-0.85). Patients with DKD, DR, and DN had eGDR values significantly lower by 1.29, 0.75, and 0.64 units, respectively, compared to those without complications.<b>Conclusion:</b> This meta-analysis highlights the potential role of eGDR as a non-invasive marker for the early detection of microvascular complications, highlighting the importance of regular eGDR monitoring to facilitate timely interventions.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 2","pages":"14791641251324612"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study.","authors":"Joshua E Lewis, Diana K Omenge, Amani R Patterson, Ogechukwu Anwaegbu, Nangah N Tabukum, Jimmie E Lewis, Wei-Chen Lee","doi":"10.1177/14791641251322909","DOIUrl":"10.1177/14791641251322909","url":null,"abstract":"<p><p>IntroductionDiabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15-25% of individuals living with diabetes and significantly contributing to healthcare costs ($9-13 billion annually in the U.S.). Without effective management, these wounds often lead to severe outcomes like amputations. This study aims to examine the association of semaglutide on DFU management.MethodsThis retrospective cohort study utilized TriNetX US Research Network data to assess the impact of semaglutide, a GLP-1 receptor agonist, on DFU outcomes between 2013 and 2023. The study compared outcomes between semaglutide users with DFU (Cohort A, <i>N</i> = 6329) and non-users with DFU (Cohort B, <i>N</i> = 118,821) across 64 healthcare organizations. We matched participants by age, gender, race, and ethnicity; however, we excluded patients with certain co-morbidities. Statistical analysis, such as chi-square analysis and risk ratio, using TriNetX software evaluated different complication outcomes.ResultsSemaglutide users with DFU demonstrated lower relative risks for complications compared to non-users. Within 1 year, semaglutide users were associated with lower relative risks for wound healing complications (0.19% vs 0.38%), chronic non-healing wounds (0.75% vs 1.23%), chronic pain (4.44% vs 8.06%), wound care (2.42% vs 4.86%), wound dehiscence (0.26% vs 0.56%), and amputation (2.34% vs 5.21%) (<i>p</i> < .05). Similar trends persisted over 5 years. While these findings highlight potential benefits of semaglutide with patients with DFU, causation cannot be inferred due to the study's observational design.ConclusionSemaglutide use was associated with favorable outcomes in patients with diabetes-related foot ulcers, including reductions in wound-related complications. While these findings suggest potential benefits of semaglutide as an adjunct in DFU management, further research is needed to confirm these associations and to better understand the mechanisms involved.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 2","pages":"14791641251322909"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of non-pharmacological sleep interventions on glycaemic measures in adults with sleep disturbances and behaviours: A systematic review and meta-analysis.","authors":"Samiul A Mostafa, Wasim Hanif, Francesca Crowe, George Balanos, Krishnarajah Nirantharakumar, Jason G Ellis, Abd A Tahrani","doi":"10.1177/14791641241307367","DOIUrl":"10.1177/14791641241307367","url":null,"abstract":"<p><strong>Background: </strong>Sleep insufficiency is known to negatively impact on glucose metabolism. Consequently, there is interest in determining the impact of improving sleep on glucose metabolism. We conducted a meta-analysis of studies that aimed at improving sleep using cognitive behavioural therapy for insomnia (CBT-I) and/or sleep hygiene or sleep extension on glucose metabolism.</p><p><strong>Methods: </strong>Searches were performed on MEDLINE, EMBASE, CINAHL and Cochrane. We included studies featuring adults≥18years, a sleep intervention and glycaemic measurements. The pooled mean differences were calculated by the inverse variance method.</p><p><strong>Results: </strong>24 studies (15 CBT-I and/or sleep hygiene; 9 sleep extension) were included. Meta-analysis of 12 studies (<i>n</i> = 2,044) of CBT-I and/or sleep hygiene demonstrated a significant reduction in HbA1c of 0.27% (95% CI 0.07, 0.47, I² 74%, <i>p</i> = 0.008) compared to control. In T2DM (<i>n</i> = 1,911; 9 studies), HbA1c level decrease was 0.43% (0.19, 0.67, I² 59%, <i>p</i> = 0.0004). There were no significant changes in fasting blood glucose analyses nor in any sleep extension intervention. For quality assessment, only 9 studies had low concern.</p><p><strong>Conclusions: </strong>Using CBT-I and/or sleep hygiene interventions led to significant reductions in HbA1c levels, which were clinically meaningful in T2DM. Addressing sleep insufficiency should be an integral part of diabetes care.</p><p><strong>Registration: </strong>PROSPERO Identification number: CRD42022376606.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 1","pages":"14791641241307367"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unraveling the causal role of sleep traits in development of diabetic retinopathy: A UK Biobank observational study and Mendelian randomization.","authors":"Yikeng Huang, Xiaoyin Xu, Xinyu Zhang, Xinyu Zhu, Bo Li, Mingming Ma, Chuandi Zhou, Chufeng Gu, Yujin Jiang, Yanlin Wu, Zhi Zheng, Shuzhi Zhao","doi":"10.1177/14791641251318319","DOIUrl":"10.1177/14791641251318319","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the potential causal role of sleep traits (STs) on diabetic retinopathy (DR).</p><p><strong>Methods: </strong>The cross-sectional study included 23,851 patients with type 2 diabetes from the UK Biobank and used multivariate logistic models to investigate the observational association between STs and DR. Genetic correlation analysis and two-sample Mendelian randomization (MR) were conducted using ST data from the UK Biobank and DR data from the FinnGen consortium to investigate the genetic and causal associations between STs and DR.</p><p><strong>Results: </strong>Patients who experienced daytime sleepiness often/all of the time had a higher risk for DR (OR: 1.40; 95% CI, 1.09-1.79; <i>p</i> = .008) compared with those who sometimes/never/rarely experienced daytime sleepiness. Genetic correlations between several STs and DR were detected by cross-trait linkage disequilibrium score regression. MR suggested a causal effect of self-reported daytime sleepiness (OR: 4.08; 95% CI, 1.44-11.61; <i>p</i> = .008), and accelerator-derived sleep duration (OR: 0.73; 95% CI, 0.54-0.98; <i>p</i> = .036) and sleep efficiency (OR: 0.54; 95% CI, 0.36-0.80; <i>p</i> = .002) on DR.</p><p><strong>Conclusions: </strong>STs may have a potential causal role for DR. Attention should be paid to the STs of patients for better prevention and treatment of DR.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 1","pages":"14791641251318319"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review and meta-analysis of randomized controlled trials of systemic antibiotics for diabetes-related foot infections.","authors":"Mei-Chuan Lee, Yi-Ming Hua, Han Siong Toh, Hui-Chen Su, Po-Jung Chen","doi":"10.1177/14791641241311293","DOIUrl":"10.1177/14791641241311293","url":null,"abstract":"<p><strong>Objective: </strong>Diabetes-related foot infections (DFIs) are prevalent in patients with diabetes mellitus, often leading to severe complications, including amputations. This study aims to assess the efficacy and safety of systemic antibiotics in DFI treatment.</p><p><strong>Research design and methods: </strong>A systematic review was conducted by searching PubMed, Cochrane databases, and Embase for randomized controlled trials up to August 4, 2024, evaluating the clinical efficacy of systemic antibiotics for DFIs. Primary outcomes were clinical efficacy and safety, comparing different antibiotic classes to penicillins. Subgroup analysis was based on DFI severity.</p><p><strong>Results: </strong>Of 24 studies, 16 were included in the meta-analysis. Linezolid showed a potential efficacy advantage over penicillins for DFIs but had more adverse effects. Clinical efficacy and safety were comparable across carbapenems and quinolones versus penicillins. Ertapenem showed no significant difference from piperacillin/tazobactam in treating moderate or severe DFIs.</p><p><strong>Conclusion: </strong>In conclusion, while linezolid may offer a potential efficacy advantage over penicillins in treating DFIs, it is associated with a higher risk of drug-related adverse effects. Penicillins demonstrate comparable clinical efficacy and safety to carbapenems and fluoroquinolones for DFI management. For moderate to severe DFIs, piperacillin/tazobactam and ertapenem are viable options, though treatment should be guided by local antimicrobial resistance patterns.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 1","pages":"14791641241311293"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.","authors":"Junya Hironaka, Emi Ushigome, Yuriko Kondo, Yoshitaka Hashimoto, Takafumi Osaka, Saori Majima, Naoko Nakanishi, Hiroshi Okada, Takafumi Senmaru, Masahide Hamaguchi, Masahiro Yamazaki, Michiaki Fukui","doi":"10.1177/14791641251318309","DOIUrl":"10.1177/14791641251318309","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the effects of oral semaglutide on the changes in food preference of Japanese patients with type 2 diabetes.</p><p><strong>Methods: </strong>This retrospective multicenter study included 75 patients with type 2 diabetes who received oral semaglutide. The primary outcome was the change in the score of brief-type self-administered diet history questionnaire (BDHQ) score 3 months after the initiation of oral semaglutide treatment. The secondary outcome was the change in the Control of Eating Questionnaire (CoEQ), HbA1c, and body mass index (BMI) after 3 months.</p><p><strong>Results: </strong>The median age, BMI, and HbA1c of the 23 participants were 64.0 years, 26.9 kg/m², and 7.6% (59 mmol/mol). The BDHQ results showed total energy was significantly reduced. Among the individual nutrients, carbohydrates most decreased. The CoEQ results particularly showed declines in cravings for something sweet, chocolate or chocolate flavored foods, and starchy foods, satisfaction at meals, frequency and intensity of food craving, difficulty of resisting the craving for food, and frequency of eating in response to cravings for food were significantly lower after 3 months. The mean HbA1c and BMI significantly decreased.</p><p><strong>Conclusions: </strong>In Japanese patients with type 2 diabetes, oral semaglutide treatment decreased total energy intake and changed food preferences.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"22 1","pages":"14791641251318309"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between osteoprotegerin and arterial stiffness in a 10-year longitudinal study of patients with type 2 diabetes.","authors":"Serena Low, Sharon Pek, Angela Moh, Jian-Jun Liu, Bhuvaneswari Pandian, Keven Ang, Wern Ee Tang, Ziliang Lim, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim","doi":"10.1177/14791641241304435","DOIUrl":"10.1177/14791641241304435","url":null,"abstract":"<p><p><b>Introduction</b>: Osteoprotegerin (OPG) inhibits vascular calcification which is central to pathogenesis of arterial stiffness. However, it promotes inflammation by upregulating expression of vascular cell adhesion molecule-1(VCAM-1), thereby contributing to arterial stiffness. We investigated longitudinal association between OPG and arterial stiffness in type 2 diabetes (T2D), causality of the association and mediation by VCAM-1. <b>Methods</b>: This was a prospective cohort study of T2D patients (<i>N</i> = 1877, mean age 57.0 ± 10.8) with 10 years' follow-up. Baseline plasma OPG was measured using immunoassay. Pulse wave velocity (PWV) was assessed using applanation tonometry. We examined association between OPG and follow-up PWV using linear mixed model. One-sample Mendelian Randomization (MR) was conducted with rs1385492 as OPG-associated single nucleotide polymorphism (SNP). <b>Results</b>: Baseline natural log (Ln)-transformed OPG was positively associated with baseline and follow-up PWV with adjusted coefficients 0.43 (95%CI 0.05, 0.80; <i>p</i> = .026) and 0.51 (95%CI 0.06 to 0.97; <i>p</i> = .028) respectively. Genetically-predicted higher levels of plasma OPG was associated with higher last follow-up PWV with coefficient 10.81 (95%CI 2.97, 18.65; <i>p</i> = .007) per unit increase in LnOPG. Higher VCAM-1 accounted for 10.2% of association between LnOPG and follow-up PWV. <b>Discussion</b>: Baseline plasma OPG was associated with higher follow-up PWV in patients with T2D, with genetic evidence from MR. This association may be mediated, at least in part, by VCAM-1.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"21 6","pages":"14791641241304435"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of lncRNA DBH-AS1 for cardiovascular events in patients with type 2 diabetes mellitus with coronary heart disease.","authors":"Xintong Wang, Yan Li, Jiaoding Tian","doi":"10.1177/14791641241303948","DOIUrl":"10.1177/14791641241303948","url":null,"abstract":"<p><strong>Background: </strong>The frequency of type 2 diabetes mellitus (T2DM) is rising annually. Coronary heart disease (CHD) is a prevalent complication affecting individuals with T2DM.</p><p><strong>Objective: </strong>The aim of this investigation was to assess the level of DBH-AS1 in T2DM with CHD, and to determine its potential role in forecasting the occurrence of significant cardiovascular events.</p><p><strong>Methods: </strong>The DBH-AS1 levels were detected by qRT-PCR. The diagnostic value of DBH-AS1 was assessed through receiver operating characteristic (ROC) curve analysis. Logistic regression was conducted to identify the risk factors for cardiovascular events among patients with T2DM with CHD. Cell proliferation was detected by Cell Counting Kit-8 (CCK-8) assay, apoptosis was detected by flow cytometry, and the concentration of inflammatory factors was detected by Enzyme Linked Immunosorbent (ELISA) kit.</p><p><strong>Results: </strong>DBH-AS1 was down-regulated in serum of both T2DM with CHD and cardiovascular events patients. Of the cardiovascular events that occurred, major events included recurrent angina (20%), cardiovascular death (7.5%), acute myocardial infarction (23.75%), severe arrhythmia (22.50%), acute heart failure (18.75%) and stroke (7.5%). And DBH-AS1 had a predictive value for each adverse of cardiovascular events. DBH-AS1 regulated the expression of miR-483-5p and affected the proliferation, apoptosis, and secretion of inflammatory factors of HCAECs.</p><p><strong>Conclusion: </strong>DBH-AS1 may serve as a predictor for the occurrence of cardiovascular events in T2DM with CHD patients.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"21 6","pages":"14791641241303948"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA-451a downregulation in liraglutide-treated individuals with diabetes: A potential cardiovascular protective mechanism.","authors":"Surachai Kongrat, Titiwat Sungkaworn, Chatchai Muanprasat, Chutintorn Sriphrapradang, Teerapat Yingchoncharoen","doi":"10.1177/14791641241278527","DOIUrl":"10.1177/14791641241278527","url":null,"abstract":"","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"21 5","pages":"14791641241278527"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11437537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-year outcomes of patients with diabetes mellitus treated with a sirolimus-eluting or a biolimus-eluting stents with biodegradable polymer. From the SORT OUT VII trial.","authors":"Jens Trøan, Evald Høj Christiansen, Kirstine Nørregaard Hansen, Ashkan Eftekhari, Lars Jakobsen, Michael Mæng, Phillip Freeman, Rebekka Vibjerg Jensen, Martin Kirk Christensen, Manijeh Noori, Julia Ellert-Gregersen, Nicolaj Brejnholt Støttrup, Johnny Kahlert, Karsten Tange Veien, Lisette Okkels Jensen","doi":"10.1177/14791641241283939","DOIUrl":"10.1177/14791641241283939","url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus is associated with higher risk of target lesion failure (TLF) after percutaneous coronary intervention. We studied the 5-year outcome in patients with diabetes mellitus treated with biodegradable polymer stents.</p><p><strong>Methods: </strong>The SORT OUT VII was a randomised trial comparing the ultrathin sirolimus-eluting Orsiro stent (O-SES) and the biolimus-eluting Nobori stent (N-BES) in an all-comer setting. Patients (<i>n</i> = 2525) were randomised to receive O-SES (<i>n</i> = 1261, diabetes: <i>n</i> = 236) or N-BES (<i>n</i> = 1264, diabetes: <i>n</i> = 235). Endpoints were TLF (a composite of cardiac death, target-lesion myocardial infarction (MI), target lesion revascularization (TLR)), definite stent thrombosis and a patient related outcome (all-cause mortality, MI and revascularization) within 5 years.</p><p><strong>Results: </strong>Patients with diabetes mellitus had higher TLF (20.6% vs 11.0%, (Rate ratio (RR) 1.85 95% confidence interval (CI): (1.42-2.40) and patient related outcome (42.0% vs 31.0%, RR 1.43 95% CI: (1.19-1.71)) compared to patients without diabetes. Among patients with diabetes mellitus, TLF after 5 years did not differ between O-SES and N-BES (21.2% vs 20.0%), RR 1.05 95% CI: (0.70-1.58), <i>p</i> = 0.81). Cardiac death, MI, TLR, and definite stent thrombosis did not differ between the groups.</p><p><strong>Conclusion: </strong>In patients with diabetes mellitus, 5-year outcomes were similar among patients treated with biodegradable polymer O-SES or N-BES.</p><p><strong>Clinical trial registration: </strong>URL: https://www.clinicaltrials.gov. Unique identifier: NCT01879358.</p>","PeriodicalId":93978,"journal":{"name":"Diabetes & vascular disease research","volume":"21 5","pages":"14791641241283939"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}